DOP2018000287A - Método para producir derivado de difenilmetano - Google Patents

Método para producir derivado de difenilmetano

Info

Publication number
DOP2018000287A
DOP2018000287A DO2018000287A DO2018000287A DOP2018000287A DO P2018000287 A DOP2018000287 A DO P2018000287A DO 2018000287 A DO2018000287 A DO 2018000287A DO 2018000287 A DO2018000287 A DO 2018000287A DO P2018000287 A DOP2018000287 A DO P2018000287A
Authority
DO
Dominican Republic
Prior art keywords
difenylmethane
producing
synthesis route
synthesis
linear
Prior art date
Application number
DO2018000287A
Other languages
English (en)
Spanish (es)
Inventor
Choi Soongyu
Yoon Hee-Kyoon
Yoon Ji-Sung
Jeong Seo Hee
Park Eun-Jung
Kong Younggyu
Song Kwang-Seop
Ju Kim Min
Ok Park So
Park Se-Hwan
Original Assignee
Dae Woong Pharma
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2018000287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma, Green Cross Corp filed Critical Dae Woong Pharma
Publication of DOP2018000287A publication Critical patent/DOP2018000287A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DO2018000287A 2016-06-17 2018-12-17 Método para producir derivado de difenilmetano DOP2018000287A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17

Publications (1)

Publication Number Publication Date
DOP2018000287A true DOP2018000287A (es) 2019-03-31

Family

ID=60664449

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000287A DOP2018000287A (es) 2016-06-17 2018-12-17 Método para producir derivado de difenilmetano

Country Status (29)

Country Link
US (2) US10640496B2 (cg-RX-API-DMAC10.html)
EP (2) EP3663292B1 (cg-RX-API-DMAC10.html)
JP (4) JP6763978B2 (cg-RX-API-DMAC10.html)
KR (2) KR102233229B1 (cg-RX-API-DMAC10.html)
CN (2) CN113651803B (cg-RX-API-DMAC10.html)
AU (1) AU2017285813B2 (cg-RX-API-DMAC10.html)
CA (2) CA3026756C (cg-RX-API-DMAC10.html)
CL (1) CL2018003645A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018014018A2 (cg-RX-API-DMAC10.html)
DK (2) DK3663292T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2018000287A (cg-RX-API-DMAC10.html)
EC (1) ECSP19000185A (cg-RX-API-DMAC10.html)
ES (2) ES2891825T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20211670T8 (cg-RX-API-DMAC10.html)
HU (1) HUE056428T2 (cg-RX-API-DMAC10.html)
MA (2) MA50774B1 (cg-RX-API-DMAC10.html)
MX (2) MX392177B (cg-RX-API-DMAC10.html)
MY (1) MY203941A (cg-RX-API-DMAC10.html)
NZ (1) NZ749398A (cg-RX-API-DMAC10.html)
PE (2) PE20190467A1 (cg-RX-API-DMAC10.html)
PH (1) PH12018550206A1 (cg-RX-API-DMAC10.html)
PL (2) PL3663292T3 (cg-RX-API-DMAC10.html)
PT (2) PT3473621T (cg-RX-API-DMAC10.html)
RS (1) RS62550B1 (cg-RX-API-DMAC10.html)
SA (2) SA518400666B1 (cg-RX-API-DMAC10.html)
SG (2) SG11201811154QA (cg-RX-API-DMAC10.html)
SI (1) SI3663292T1 (cg-RX-API-DMAC10.html)
TN (1) TN2018000437A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017217792A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
BR112021002523A2 (pt) 2018-08-13 2021-05-04 Daewoong Pharmaceutical Co., Ltd. método para preparar um composto
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
US12497390B2 (en) 2020-02-27 2025-12-16 Daewoong Pharmaceutical Co., Ltd. Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
WO2022051980A1 (zh) * 2020-09-10 2022-03-17 广东莱佛士制药技术有限公司 用于制备sglt抑制剂中间体的合成方法
CN113200860B (zh) * 2021-04-29 2024-07-30 爱斯特(成都)生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
KR20230046784A (ko) * 2021-09-30 2023-04-06 주식회사 대웅제약 이나보글리플로진을 포함하는 약학 조성물
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR102994906B1 (ko) * 2022-01-14 2026-07-24 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044194A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
WO2024072079A1 (ko) 2022-09-29 2024-04-04 주식회사 대웅제약 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물
US20260130933A1 (en) 2022-10-05 2026-05-14 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin
AU2023412900A1 (en) 2022-12-21 2025-06-12 Daewoong Therapeutics Inc. Eye drop-type pharmaceutical composition containing envogliflozin
KR20240107660A (ko) * 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
CN122438688A (zh) 2023-12-27 2026-07-21 株式会社大熊制药 包含依那格列净作为活性成分的用于预防或治疗斑秃的药物组合物
KR102837941B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837948B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102853437B1 (ko) * 2024-11-13 2025-09-04 대웅바이오(주) 연속반응 공정을 이용한 이나보글리플로진 합성방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
CN104109155A (zh) * 2003-08-01 2014-10-22 田边三菱制药株式会社 新颖化合物
UA107175C2 (uk) 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
BRPI0916395A2 (pt) 2008-07-30 2016-02-16 Ferrer Int compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
JP5876570B2 (ja) * 2011-06-01 2016-03-02 グリーン・クロス・コーポレイションGreen Cross Corp. Sglt2阻害剤としての新規のジフェニルメタン誘導体
US9340521B2 (en) 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2017217792A1 (ko) 2017-12-21
RU2021129636A (ru) 2021-11-22
JP2021152054A (ja) 2021-09-30
CO2018014018A2 (es) 2019-03-08
KR102233229B1 (ko) 2021-03-29
CL2018003645A1 (es) 2019-03-22
JP2020117528A (ja) 2020-08-06
JP7773506B2 (ja) 2025-11-19
MA50774B1 (fr) 2022-02-28
NZ749398A (en) 2020-01-31
JP2019521985A (ja) 2019-08-08
MX2021008988A (es) 2022-05-05
MY203941A (en) 2024-07-25
EP3473621B1 (en) 2021-08-04
JP7669206B2 (ja) 2025-04-28
CA3081033A1 (en) 2017-12-21
MX392177B (es) 2025-03-19
PE20240590A1 (es) 2024-03-21
KR20210036892A (ko) 2021-04-05
MA44545B2 (fr) 2020-11-30
PT3473621T (pt) 2021-10-04
PL3663292T3 (pl) 2022-01-17
MX385640B (es) 2025-03-18
AU2017285813A1 (en) 2019-01-17
PL3473621T3 (pl) 2022-01-10
JP6763978B2 (ja) 2020-09-30
HUE056428T2 (hu) 2022-02-28
MA44545B1 (fr) 2020-05-29
ECSP19000185A (es) 2019-01-31
CN109311861B (zh) 2021-08-24
CA3026756A1 (en) 2017-12-21
SG10201911782RA (en) 2020-02-27
KR20170142904A (ko) 2017-12-28
JP7352509B2 (ja) 2023-09-28
SI3663292T1 (sl) 2022-01-31
RS62550B1 (sr) 2021-12-31
TN2018000437A1 (en) 2020-06-15
CA3081033C (en) 2022-04-12
CA3026756C (en) 2021-03-02
KR102379584B1 (ko) 2022-03-29
RU2019101056A3 (cg-RX-API-DMAC10.html) 2020-07-17
ES2898336T3 (es) 2022-03-07
RU2019101056A (ru) 2020-07-17
JP2023145481A (ja) 2023-10-11
US10889574B2 (en) 2021-01-12
SA518400666B1 (ar) 2021-11-30
MA50774A1 (fr) 2021-03-31
EP3473621A1 (en) 2019-04-24
CN113651803A (zh) 2021-11-16
ES2891825T3 (es) 2022-01-31
MA44545A1 (fr) 2019-10-31
CN113651803B (zh) 2022-10-28
EP3473621A4 (en) 2020-03-11
BR112018076243A2 (pt) 2019-03-26
PE20190467A1 (es) 2019-04-04
MX2018015647A (es) 2019-04-11
HRP20211670T1 (hr) 2022-02-18
SA521422474B1 (ar) 2023-11-02
AU2017285813B2 (en) 2020-02-06
CN109311861A (zh) 2019-02-05
DK3473621T3 (da) 2021-09-06
PH12018550206A1 (en) 2019-09-30
US20190382390A1 (en) 2019-12-19
DK3663292T3 (da) 2021-10-25
HRP20211670T8 (hr) 2022-03-18
SG11201811154QA (en) 2019-01-30
EP3663292B1 (en) 2021-09-01
US10640496B2 (en) 2020-05-05
PT3663292T (pt) 2021-11-08
US20190169174A1 (en) 2019-06-06
EP3663292A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
CO2018014018A2 (es) Método para producir derivado de difenilmetano
MX2021005598A (es) Sintesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras.
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
CL2019000844A1 (es) Compuesto de piridina.
BR112016012883A2 (pt) Métodos e composições para aprimorar o rendimento de milho
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
MX2016017355A (es) Lipido que comprende acido docosapentaenoico.
CU24377B1 (es) Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EA201500738A1 (ru) Способ получения замещенных оксиранов и триазолов
MX353307B (es) Proceso para la preparacion de inhibidores del cotransportador de glucosa dependiente de bencilbencen sodio 2 (sglt2).
CO6640282A2 (es) Barra de limpieza que comprende arcilla y/o talco
MX2016013555A (es) Produccion de 4-hidroxi-4-metil-tetrahidropiranos 2-sustituidos a partir de materiales de partida que contienen 2-alquil-4,4-dimetil-1,3-dioxanos.
UA116825C2 (uk) Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу
AR085052A1 (es) Metodos para producir un compuesto profarmaco inhibidor de la union al vih e intermediarios
GB2504245A (en) Synthesis and use of glycoside derivatives of propofol
MX2017011407A (es) Metodo para producir esteres de tetrahidropiranilo.
CL2024003302A1 (es) Oligonucleótidos antisentido syf2.
EA201690245A1 (ru) Оптимизированный способ получения композиции, содержащей изомальтулозу
MX2019006959A (es) Procesos para la preparacion de compuestos de pirimidinilciclopentano.
CL2022001806A1 (es) Método para producir derivado de difenilmetano.
EA201591449A1 (ru) Способы получения противораковых композиций
IN2013MU01219A (cg-RX-API-DMAC10.html)
MX2015015792A (es) Metodo para producir dehidro-óxido de rosas.
AR102166A1 (es) Método de fabricación de un péptido derivado de tapsigargina
MX2016008281A (es) Procedimientos mejorados para producir propilenglicol.